Tyche Industries Ltd. Stock Analysis 532384.BO

Tyche Industries Ltd. engages in the manufacture and processing of active pharmaceutical ingredients and intermediates. The company employs 162 full-time employees The company went IPO on 2000-09-25. The firm operates through the Bulk Drugs segment. Its APIs include Sertraline HCI, Racecadotril, Palonosetron HCI, Silodosin, Solifenacin Succinate, Tamsulosin HCI, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide Fumarate, Atazanavir, Rupatadine Fumarate, Glucosamine HCI, Glucosamine Sulfate KCL, Glucosamine Sulfate NaCl, Nitrofurantoin Monohydrate, Nitrofurantoin Anhydrous and Nitrofurantoin Macrocrystal and others. Its intermediates include 4-(3,4-Dichlorophenyl)-1-tetralone, 1-Benzylpiperidine-4-Carboxaldehyde (BPCA), 3-Hydroxymethyl quinuclidine Hcl, and others. Its chiral intermediates include S-(+)-3-Quinuclidinol, R-(-)-3-Quinuclidinol and others. The firm's nutraceuticals include Glucosamine Hydrochloride, Glucosamine Sulfate Potassium Chloride and Glucosamine Sulfate Sodium Chloride.